Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study Evaluating the Safety and Pharmacokinetics of Ataluren in Children From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy

NCT04336826 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT04336826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04336826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study Evaluating the Safety and Pharmacokinetics of Ataluren in Children From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy
Lead sponsor
PTC Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
December 29, 2021
Completion date
August 7, 2023
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nonsene mutation duchenne muscular dystrophy